RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Clinical trial NCT05127590 · UNKNOWN

Trial details

NCT number: NCT05127590
Sponsor: Ribon Therapeutics, Inc.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Squamous Non-Small Cell Lung Carcinoma

Start date: 2022-03-15
Primary completion: 2023-11-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.